The patient was well until the age of 80 and then, gradually developed hypoxemia with hypercapnia. She was admitted again and was treated with a cephalosporin and the respiratory tract infection settled. However, hypoxemia with hypercapnia was not controlled and she died from respiratory failure.
Comment
It is understood that Kartagener's syndrome is caused by ciliary dysfunction. 4 The energy for ciliary motility is derived from activity of adenosine triphosphatase in the dynein arms, which are located on the A subunit of the outer microtubules. 5 The earliest reports recognized that the complete absence of both dynein arms in Kartagener's syndrome were the basis of the pathophysiology. 4, 6 Several types of ultrastructural abnormality in other parts of the cilia have now been described as the cause of ciliary dyskinesia. 7 In our patient, a lack of inner and outer dynein arms of cilia was observed on electron microscopic examination. An important determinant of survival in bronchiectasis is thought to be FEV 1 , but her FEV 1 at the age of 65 years was only 0.74 L, and it was 0.66 L at the age of 71 years old.
The recent trend in the treatment of bronchiectasis, which is used in patients with Kartagener's syndrome, is long-term antibiotic therapy to decrease the inflammatory load in the bronchial tree. 8 In Japan, some of the macrolide antibiotics, such as erythromycin have been shown to be effective in reducing infection in patients with chronic bronchial suppuration. 9 The effect of macrolide antibiotic therapy cannot be ascribed to its antibacterial action 9,10 but rather, its immunoregulatory function, such as inhibition of neutrophil chemotaxis and superoxide production in vitro. 10, 11 In our case, macrolide antibiotic therapy for respiratory tract infection was started at the age of 65. Over the next few years the patient had frequent admissions to our hospital with pulmonary problems but was in stable condition with continuous macrolide therapy for several years. Chronic or acute on chronic respiratory tract infection was controlled. Thereafter her respiratory condition deteriorated gradually and she died at the age of 80 years. The late age of presentation and death in our patient was unusual, however, two cases more than 70 years old have already been reported. 2, 3 We suppose that it may be possible for patients with Kartagener's syndrome to live a full span with optimal therapy for respiratory tract infection and control progression of the disease.
